Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Lung, Respiratory and Thoracic Cancer

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Lung Cancer.

Paz-Ares LG, Pérol M, Ciuleanu TE, Kowalyszyn RD, Reck M, Lewanski CR, Syrigos K, Arrieta O, Prabhash K, Park K, Pikiel J, Göksel T, Lee P, Zimmermann A, Cuyun Carter G, Alexandris E, Garon EB

Lung, Respiratory and Thoracic Cancer

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer

JAMA Oncol.

Li B, Cui Y, Diehn M, Li R

doi: 10.1001/

Gastrointestinal CancerGenitourinary CancerLung, Respiratory and Thoracic Cancer

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

BMC Cancer.

Casadei Gardini A, Chiadini E, Faloppi L, Marisi G, Delmonte A, Scartozzi M, Loretelli C, Lucchesi A, Oboldi D, Dubini A, Frassineti GL, Ulivi P

doi: 10.1186/s12885-016-2463-2.

Lung, Respiratory and Thoracic Cancer

First-line treatment of ALK-positive NSCLC

healthbook TIMES Oncology Hematology

Bouchaab H

doi: 10.36000/hbT.OH.2019.02.008

Lung, Respiratory and Thoracic CancerLymphoma

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Lancet Oncol.

Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E

doi: 10.1016/S1470-

Lung, Respiratory and Thoracic CancerRadio-Oncology

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial

Lancet Respir Med.

Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, Liu X, Yan HH, Tan FL, Zhong W, Wu YL

doi: 10.1016/S2213-

Lung, Respiratory and Thoracic Cancer

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a metaanalysis

Oncotarget.

Kim JH, Kim HS, Kim BJ

doi: 10.18632/oncotarget.18703.

Lung, Respiratory and Thoracic Cancer

Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report

Clin Drug Investig.

Giusti R, Mazzotta M, Iacono D, Lauro S, Marchetti P

doi: 10.1007/s40261-017-0515-2.

Related content

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer

Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report

First-line treatment of ALK-positive NSCLC

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a metaanalysis

Complete Tumor Response with Afatinib 20 mg Daily in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report